30 closest matches · ranked by relevance
Lymphoma
Primary: Percentage of Participants With Indolent NHL Achieving CR or Partial Response (PR) According to International Response Criteria for NHL — 66.7 Percentage of Participants
Ann Arbor Stage III Grade 1 Follicular Lymphoma · Ann Arbor Stage III Grade 2 Follicular Lymphoma · Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma
Primary: Number of Participants With Best Overall Disease Response — 0; 56; 17; 8 Participants
Lymphoma
Primary: Time to Rituximab Failure (TTRF) — 3.92; 4.32; 1.39; 4.83 years — p=0.33
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Response Rate — 29 percentage of participants
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Follicular Lymphoma · Small Lymphocytic Lymphoma · Lymphoplasmacytic Lymphoma
Primary: Overall Response Rate — 57.6 percentage of participants — p=< 0.0001
Lymphoma
Primary: Assessment of Tumor Response — 30.3; 54.5 percentage of participants
Non-Hodgkins Lymphoma
Primary: Percentage of Participants With Response — 23.3 percentage of participants
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma · Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants
Indolent Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 59.7 percentage of participants — p=<=0.0001
Follicular Lymphoma · Marginal Zone Lymphoma · Indolent Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment — 92; 69 percentage of participants
Leukemia · Lymphoma
Primary: Maximum Tolerated Dose — 1.8; 1.5 mg/m^2 of Bortezomib
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Lymphoma
Primary: Overall Response Rate (Complete and Partial Response) — 46 percentage of participants
Lymphoma, Non-Hodgkin
Primary: Optimal Bendamustine Dosage for Further Studies — 60 mg/m^2
Lymphoma, Non-Hodgkin's
Primary: Participants Categorized by Best Response as Determined by Central Review — 7; 21; 40; 71 Participants
Grade 3a Follicular Lymphoma · Recurrent Follicular Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide When Given With Obinutuzumab Defined as the Highest Dose Level Have Been Treated With Less Than 2 Instances of Dose Limiting…
Indolent Non-Hodgkin's Lymphoma · Follicular Lymphoma · Small Lymphocytic Lymphoma
Primary: Overall Safety of Idelalisib — 88.9; 27.8; 55.6; 83.3 percentage of participants
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Primary: Overall Response Rate — 12 Participants — p=0.044
Lymphoma, Non-Hodgkin
Primary: Objective Response Rate (ORR) Based on Independent Review-Part A — 43.75; 27.08 percentage of participants — p=0.0001
Non-Hodgkin's Lymphoma
Primary: Maintenance II: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for…
Lymphoma, Non-Hodgkin
Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…
Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lymphoma, Mantle-Cell
Primary: Maximum Tolerated Dose — 2.24 mg/m^2
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…
Lymphoma,Non-Hodgkin
Primary: Progression Free Survival (PFS) Based on Independent Central Review. — 21.5; 13.8; 23.2; 13.8 Months — p=0.000002
Non-Hodgkin's Lymphoma
Primary: Number of Participants With Dose Limiting-Toxicities (DLTs) After SC Administration — 0; 1; 1; 0 Participants
Non-Hodgkin's Lymphoma · Hodgkin's Disease
Primary: Phase 1: Determination of Maximum Tolerated Dose (MTD) First Without and Then With Administration of Prophylactic G-CSF. — 2; 3; 4; 5 mg/m2
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Lymphoma
Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants
Lymphoma
Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants